<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>EOSS_MMRM | Home</title>
  <style>
* {
  box-sizing: border-box;
}

.navbar>.container .navbar-brand, .navbar>.container-fluid .navbar-brand {
  margin-left: auto;
}
 
html, body {
  font-family: 'Arial', Helvetica, sans-serif;
  line-height: 1.2em;
  font-size: 16px;
  padding: 10px;
  background-color: #ffffff;
}

.header {
  background-color: #ffffff; 
  /*color: #0C5449;*/
  padding: 0px;
}

    
    
h1, h2, h3 {
  padding-top: 5px;
  padding-bottom: 5px;
}

h4 {
  padding-left: 10px;
  padding-top: 10px;
  padding-bottom: 10px;
}

p {
  line-height: 1.5;
  margin: 10px 0px;
  padding-bottom: 5px;
}

.aboutus-p {
  font-family: Arial, Helvetica, sans-serif;
  background-color: #f1f5f5; 
  line-height: 1.2em;
  padding: 10px;
}

.center {
  margin-left: auto;
  margin-right: auto;
}

.footer {
  background-color: #0C5449;
  color: #ffffff;
  text-align: center;
  font-size: 12px;
  padding: 10px;
}
</style>
</head>


<body>
  <div class="header">
      <h1><span>Welcome to EOSS_MMRM V1.0</span></h1>
      
<p>The ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials has been implemented by many regulatory agencies since 2019. Sample size and power calculation, as critical components in trial design, need to be aligned with the chosen estimands and intercurrent event (ICE) strategies that reflect trial objectives.</p>
 

<p>EOSS_MMRM V1.0 performs sample size and power simulations with an estimand-oriented approach for clinical trials utilizing MMRM (Mixed-effect Model for Repeated Measures) in their primary endpoint analysis, and it handles intercurrent events (ICEs) using treatment policy or hypothetical strategies.</p>


<p>EOSS_MMRM V1.0 enables the specification of expected efficacy at post-ICE follow-up visits, along with missing data patterns and extent. This capability provides the study sponsor and key stakeholders with a better understanding of how different ICE strategies and missing data will impact statistical power before study execution, thereby enhancing the understanding and characteristics of the trial.</p>

 
<p>A novel feature of EOSS_MMRM V1.0 is the option to generate simulated data for a response variable along with randomization. This feature makes EOSS_MMRM V1.0 suitable for classroom teaching purposes. Instructors can utilize both the dynamic user interface and the R functions to teach R scripting courses.</p>
</div>
    
<br>

    
<div class="aboutus-p">
<h2><span style="font-weight:bold;">About Us </span></h2>
      <p>EOSS_MMRM V1.0 is the result of a collaboration among an international group of researchers, including biostatisticians from the pharmaceutical industry and statisticians from academia. EOSS_MMRM V1.0 has been published in PHUSE US Connect 2024 archive: 
<a href="https://phuse.s3.eu-central-1.amazonaws.com/Archive/2024/Connect/US/Bethesda/PAP_AS03.pdf" target="_blank">Paper</a> and <a href="https://phuse.s3.eu-central-1.amazonaws.com/Archive/2024/Connect/US/Bethesda/PRE_AS03.pdf" target="_blank">Presentation</a>.
</p>


<p>Jing Dai, Jazz Pharmaceuticals and Wayne State University,
<a href="https://www.linkedin.com/in/jingdai9527/" target="_blank" >LinkedIn</a></p>

<p>Valmira Hoxhaj, Jazz Pharmaceuticals,
<a href="https://www.linkedin.com/in/valmira-hoxhaj-05238b32/" target="_blank">LinkedIn</a></p>

<p>Liz Gardener, Jazz Pharmaceuticals,
<a href="https://www.linkedin.com/in/liz-gardener-405ba012b/?originalSubdomain=uk" target="_blank">LinkedIn</a> </p>

<p>Dan Checketts, Jazz Pharmaceuticals,
<a href="https://www.linkedin.com/in/daniel-checketts-456a0240/?originalSubdomain=uk" target="_blank">LinkedIn</a></p>

<p>Xiaoli Kong, Wayne State University,
<a href="https://www.linkedin.com/in/xiaoli-kong-29040095/" target="_blank">LinkedIn</a></p>
 
</div>   
    
<!--
<div class="footer">
  <p>&copy; 2024</a></p>
</div>
-->


</body>
</html>
